Insider buying last 90 days
No open-market insider purchases were filed for BTSG in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
BrightSpring climbed this week on the back of its Q3 2026 results, reported on 30 October, which showed revenue of $4.2B, up 26% year over year, adjusted EBITDA of $228 million, up 42%, and EPS of $0.54 against an estimate of $0.47. Pharmacy Solutions revenue rose 26% to $3.7B, with specialty and infusion growth of 34% and script growth of 29%, while Provider Services revenue grew 31% to $481 million. The company raised its 2026 guidance and pointed to continued organic growth into 2027, with coverage noting the stock's 11.3% weekly gain alongside commentary on its valuation relative to peers in the medical services sector.
BTSG closed at $69.15, up 3% on the day, and sits well above both its 50-day average of $60.96 and its 200-day average of $55.54, with the shorter average above the longer one. The GekkoIndex reading of 48.6 places the stock in the Neutral zone. Against a Gekko Fair Value of $62.83, the price stands 10.1% above that level, a gap flagged as a headwind in the latest reading.
The next earnings date falls on 26 February 2027, 108 days out and beyond a typical 20-trading-day hold. No insider, Congress or unusual options activity is recorded in the current windows. Analyst coverage from 9 firms is unanimously rated buy, with a consensus target of $83.21, implying 20.3% upside from current levels. Worth noting is the recent run-up against the fair value gap as the stock digests its post-earnings move.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
BrightSpring Health Services scores 2 supportive, 1 mixed and 1 headwind across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed1 headwind
Above 50 and 200-day
Close $71.21 is above the 50-day ($61.93) and 200-day ($56.19) averages, and the 50-day is above the 200-day.
See the chart48.1, Neutral
Reading 48.1 is in the Neutral zone.
See the GekkoIndex11.0% above
Price is 11% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 103 days
Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
BrightSpring Health Services closed at $71.21 on Nov 13, 2026, +111.7% over the past year, inside a 52-week range of $30.64 to $73.75.
Use the left and right arrow keys to read daily values.
Put BTSG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
BrightSpring Health Services provides healthcare services delivered in patients' homes and local communities across the United States. Its work centers on pharmacy services alongside medical provider support, combining clinical treatment with everyday assistance for those who need it. The company is recognized for bringing this kind of home and community based care to a wide range of patients rather than requiring facility visits.
Care is delivered by clinical staff and licensed pharmacists who work directly with patients. The people served include those covered by Medicare, Medicaid, and private insurance plans, reflecting a customer base that spans public and private payers.
The company was founded in 1974 and is headquartered in Louisville, Kentucky. It previously operated under the name Phoenix Parent Holdings Inc. before adopting its current name, BrightSpring Health Services, Inc., in May 2021. Shares of the company are listed on the NASDAQ under the ticker BTSG.
BrightSpring Health Services’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.1, in the Neutral zone, down 1.4 points over five sessions.
Down 1.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | +3.1% | +6.6% | ||
| Accumulation | 160 | +1.1% | +10.6% | ||
| Neutral (current zone) | 425 | +1.5% | +5.0% | ||
| Distribution | 89 | +1.7% | +4.7% | ||
| Selling | 5 | Too few readings yet | |||
Average BTSG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
BrightSpring Health Services trades 11.0% above Gekko Fair Value of $64.15, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what BrightSpring Health Services shares are worth, recalculated every trading day.
$64.15
Gekko Fair Value, Nov 14, 2026
11.0% Overvalued
At the end of Sep 2026 the price was 8.5% below the estimate.
No open-market insider purchases were filed for BrightSpring Health Services, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BTSG in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BTSG were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
BrightSpring Health Services has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold BTSG.
BrightSpring Health Services reports on Feb 26, 2027, before the open (103 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 26, 2027
Expected before the open, 103 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 30, 2026 | $0.54 est $0.47 | $4.21B est $3.88B | +10.0% |
| Jul 31, 2026 | $0.45 est $0.37 | $3.87B est $3.66B | −17.0% |
| May 1, 2026 | $0.39 est $0.31 | $3.61B est $3.39B | +11.6% |
| Feb 27, 2026 | $0.33 est $0.25 | $3.55B est $3.38B | +3.6% |
| Oct 31, 2025 | $0.30 est $0.26 | $3.33B est $3.17B | +2.1% |
| Aug 1, 2025 | $0.13 est $0.22 | $3.15B est $3.17B | −6.2% |
| May 2, 2025 | $0.19 est $0.08 | $2.88B est $2.90B | +18.2% |
| Nov 1, 2024 | $0.11 est $0.17 | $2.91B est $2.94B | +12.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for BrightSpring Health Services is $83.21, +16.9% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 3 | Morgan Stanley | $80 | +12.3% |
| Nov 2 | UBS | $92 | +29.2% |
| Nov 2 | Leerink Partners | $92 | +29.2% |
| Nov 2 | TD Cowen | $84 | +18.0% |
| Nov 2 | Wells Fargo | $82 | +15.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BrightSpring Health Services’s market cap is $14.17B, with a P/E ratio of 50.7 and revenue of $15.25B over the last twelve months.
3 headlines about BrightSpring Health Services from the past week, newest first, each linking to the publisher.
BrightSpring Health Services’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
| DVADaVita | Accumulation | 25.6% below |
A peer links to its own page where one exists.
BrightSpring Health Services’s market cap is $14.17B at the Nov 13, 2026 close of $71.21, with 199.0M shares outstanding. The shares trade on a P/E ratio of 50.7.
The consensus analyst 12-month price target for BrightSpring Health Services is $83.21, +16.9% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate BrightSpring Health Services is overvalued: the Nov 13, 2026 close of $71.21 is 11.0% above Gekko Fair Value of $64.15. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
BrightSpring Health Services is expected to report on Feb 26, 2027, before the market opens (103 days away). Analysts expect earnings of $0.56 per share on revenue of $4.35B. BrightSpring Health Services beat the earnings estimate in 6 of its last 8 reports, moving 10.1% on average across the report.
BrightSpring Health Services’s 52-week high is $73.75 and its 52-week low is $30.64; it closed at $71.21 on Nov 13, 2026, +111.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.